Screening & Prevention — MCQs
On this page
A 52-year-old woman attends for discussion about lifestyle modification. She has a BMI of 28 kg/m², drinks 2 glasses of wine on most evenings, and works long hours in a sedentary office job. She wants to reduce her cardiovascular risk. Her father had a myocardial infarction aged 68. On examination, her BP is 132/78 mmHg. Blood tests show total cholesterol 5.2 mmol/L, HDL 1.1 mmol/L, and HbA1c 38 mmol/mol. What single lifestyle intervention would provide the greatest cardiovascular benefit?
A 65-year-old man attends for his NHS AAA screening appointment. He is asymptomatic and has no significant past medical history. The ultrasound scan shows an infrarenal aortic diameter of 2.8 cm. His blood pressure is 138/82 mmHg, and he is a non-smoker who stopped 10 years ago. What is the most appropriate management for this patient?
A 48-year-old woman attends for smoking cessation support. She smokes 20 cigarettes daily and has a 30 pack-year history. She has tried nicotine replacement therapy (NRT) patches before without success. She is motivated to quit and asks about varenicline. She has a history of depression treated with sertraline 50 mg daily, which is well-controlled. She has no other medical conditions. What is the most appropriate advice regarding varenicline?
A 44-year-old woman with a BMI of 37 kg/m² attends for weight management review. She has lost 4 kg (4% of baseline weight) over the past 3 months following dietary modification and increased physical activity. She asks about adding orlistat. She has no comorbidities. Laboratory results show normal renal and liver function. What advice should be given about continuing weight loss management?
A 55-year-old man with schizophrenia attends for his annual physical health check. He takes olanzapine 20 mg daily. His BMI is 33 kg/m², waist circumference 108 cm, blood pressure 138/86 mmHg, fasting glucose 6.2 mmol/L, HbA1c 43 mmol/mol, total cholesterol 5.4 mmol/L, HDL 0.9 mmol/L, and triglycerides 2.8 mmol/L. Which diagnosis is most likely based on these findings?
A 72-year-old woman attends for review. She has a 3.5 cm infrarenal abdominal aortic aneurysm (AAA) detected 18 months ago through the NHS screening programme. Her latest ultrasound shows the aneurysm has grown to 4.8 cm (increase of 1.3 cm in 18 months). She is asymptomatic. What is the most appropriate next step in her management?
A 59-year-old man attends for lifestyle advice. He drinks 4 units of alcohol daily (28 units per week), exclusively in the evenings. He has no alcohol-related health problems and scores 8 on the AUDIT questionnaire. According to NICE guidance on alcohol interventions, what is the most appropriate initial management?
A 36-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She asks about HPV vaccination. She was too old to receive the HPV vaccine in school but wonders if vaccination now would be helpful. What is the most appropriate advice regarding HPV vaccination in this situation?
A 68-year-old man with type 2 diabetes attends following his diabetic eye screening. The report states 'R1M1S0' for the right eye and 'R1M0S0' for the left eye. What action should be taken based on these grading results?
A 42-year-old woman with a BMI of 34 kg/m² attends for weight management advice. She has tried multiple diets without sustained success. She asks about orlistat. Her blood pressure is 142/88 mmHg and HbA1c is 41 mmol/mol. According to NICE guidance, what is the minimum BMI threshold at which orlistat can be prescribed for this patient?
Screening & Prevention UK Medical PG Practice Questions and MCQs
Question 21: A 52-year-old woman attends for discussion about lifestyle modification. She has a BMI of 28 kg/m², drinks 2 glasses of wine on most evenings, and works long hours in a sedentary office job. She wants to reduce her cardiovascular risk. Her father had a myocardial infarction aged 68. On examination, her BP is 132/78 mmHg. Blood tests show total cholesterol 5.2 mmol/L, HDL 1.1 mmol/L, and HbA1c 38 mmol/mol. What single lifestyle intervention would provide the greatest cardiovascular benefit?
- A. Increase physical activity to at least 150 minutes of moderate intensity exercise per week (Correct Answer)
- B. Reduce alcohol intake to within recommended limits of 14 units per week
- C. Reduce BMI to below 25 kg/m² through dietary modification
- D. Adopt a Mediterranean-style diet rich in fruits, vegetables, and unsaturated fats
- E. Reduce total cholesterol through dietary changes including reducing saturated fat intake
Explanation: ***Increase physical activity to at least 150 minutes of moderate intensity exercise per week*** - Increasing physical activity directly targets the patient's **sedentary lifestyle**, a major modifiable risk factor for cardiovascular disease. - Regular exercise provides broad benefits including improved **endothelial function**, increased **HDL cholesterol**, better **insulin sensitivity**, and reduced **blood pressure**, often independently of weight loss. *Reduce alcohol intake to within recommended limits of 14 units per week* - The patient consumes approximately **10-14 units per week** (2 glasses of wine on most evenings), which is already at or near the current **recommended limits** for women. - While moderation is important, further reduction would likely offer less incremental cardiovascular benefit compared to addressing her significant **physical inactivity**. *Reduce BMI to below 25 kg/m² through dietary modification* - A BMI of 28 kg/m² indicates she is **overweight**, but addressing her complete lack of movement from a **sedentary job** offers a more immediate and impactful cardiovascular benefit. - The metabolic benefits of **exercise** occur even without significant weight loss and often precede substantial BMI reduction. *Adopt a Mediterranean-style diet rich in fruits, vegetables, and unsaturated fats* - While a **Mediterranean-style diet** is excellent for cardiovascular health, the patient's most prominent unaddressed risk factor is her **sedentary lifestyle**. - Initiating regular physical activity provides a more comprehensive and direct impact on multiple cardiovascular risk factors for a previously inactive individual. *Reduce total cholesterol through dietary changes including reducing saturated fat intake* - Her **total cholesterol (5.2 mmol/L)** is only mildly elevated, and dietary changes typically result in modest reductions of around **5-10%**. - Physical activity offers a more holistic benefit by simultaneously improving **blood pressure**, **glucose metabolism**, and the **lipid profile**, making it a more impactful single intervention here.
Question 22: A 65-year-old man attends for his NHS AAA screening appointment. He is asymptomatic and has no significant past medical history. The ultrasound scan shows an infrarenal aortic diameter of 2.8 cm. His blood pressure is 138/82 mmHg, and he is a non-smoker who stopped 10 years ago. What is the most appropriate management for this patient?
- A. Discharge from screening programme with no further surveillance required (Correct Answer)
- B. Arrange repeat ultrasound surveillance in 12 months
- C. Refer to vascular surgery for consideration of surgical repair
- D. Arrange CT angiogram to further assess the aneurysm
- E. Arrange repeat ultrasound surveillance in 3 months
Explanation: ***Discharge from screening programme with no further surveillance required***- The patient's aortic diameter is **2.8 cm**, which is below the **3.0 cm threshold** used by the **NHS AAA Screening Programme** to define an aneurysm.- When the scan shows an aorta measuring **less than 3.0 cm**, the result is considered **normal**, and no further follow-up or screening is necessary for that individual.*Arrange repeat ultrasound surveillance in 12 months*- This management is reserved for patients with a **small aneurysm**, defined as an aortic diameter between **3.0 cm and 4.4 cm**.- Since this patient's measurement is below 3.0 cm, **annual surveillance** is not indicated as he does not have an abdominal aortic aneurysm.*Refer to vascular surgery for consideration of surgical repair*- Urgent referral for surgical repair is indicated when the aortic diameter is **5.5 cm or larger** (large aneurysm) or if it **expands rapidly**.- Referral is also indicated if the patient is **symptomatic**, but this patient is asymptomatic with a **normal aortic diameter**.*Arrange CT angiogram to further assess the aneurysm*- **CT angiography** is typically used for **pre-operative planning** once an aneurysm reaches the threshold for intervention or if there is diagnostic uncertainty on ultrasound.- It is never the first-line investigation or follow-up for a measurement that falls within the **normal range (<3.0 cm)**.*Arrange repeat ultrasound surveillance in 3 months*- **3-monthly (quarterly) surveillance** is the standard protocol for **medium-sized aneurysms** measuring between **4.5 cm and 5.4 cm**.- This patient's measurement is significantly lower than this threshold, making frequent monitoring clinically unnecessary and not cost-effective.
Question 23: A 48-year-old woman attends for smoking cessation support. She smokes 20 cigarettes daily and has a 30 pack-year history. She has tried nicotine replacement therapy (NRT) patches before without success. She is motivated to quit and asks about varenicline. She has a history of depression treated with sertraline 50 mg daily, which is well-controlled. She has no other medical conditions. What is the most appropriate advice regarding varenicline?
- A. Varenicline is contraindicated due to her history of depression
- B. Varenicline can be prescribed with close monitoring for neuropsychiatric symptoms (Correct Answer)
- C. Varenicline should not be used in combination with any antidepressants
- D. She should try combination NRT before considering varenicline
- E. Varenicline is only licensed for patients who have failed two attempts with NRT
Explanation: ***Varenicline can be prescribed with close monitoring for neuropsychiatric symptoms*** - **Varenicline** is a highly effective first-line smoking cessation medication that can be used in patients with a history of **stable mental health conditions**, such as well-controlled depression. - While initial concerns existed, the **EAGLES trial** demonstrated that the risk of serious **neuropsychiatric adverse events** with varenicline is comparable to placebo, even in individuals with a psychiatric history, provided they are closely monitored. *Varenicline is contraindicated due to her history of depression* - A history of **well-controlled depression** (especially while on stable medication like **sertraline**) is a **precaution**, not an absolute **contraindication**, for varenicline use. - Patients should be advised to report any **mood changes** or unusual behavior, but the medication can still be prescribed with appropriate monitoring. *Varenicline should not be used in combination with any antidepressants* - There are no clinically significant pharmacokinetic interactions between **varenicline** and **SSRIs** like **sertraline**, making their co-administration generally safe. - The main concern with psychiatric medications during smoking cessation relates to changes in the metabolism of certain drugs (e.g., clozapine) once smoking stops, rather than direct interaction with varenicline. *She should try combination NRT before considering varenicline* - The patient has already tried **NRT patches** without success, indicating a need for a different approach. **NICE guidelines** endorse varenicline as a first-line option, alongside NRT and bupropion. - Given her previous failure with NRT monotherapy and strong motivation, offering a more effective agent like **varenicline** is a clinically appropriate and often preferred next step. *Varenicline is only licensed for patients who have failed two attempts with NRT* - This statement is incorrect; **varenicline** is licensed as a **first-line pharmacotherapy** for smoking cessation and does not require any prior failed attempts with NRT. - It can be offered as the initial treatment option based on patient preference and clinical judgment, given its proven efficacy.
Question 24: A 44-year-old woman with a BMI of 37 kg/m² attends for weight management review. She has lost 4 kg (4% of baseline weight) over the past 3 months following dietary modification and increased physical activity. She asks about adding orlistat. She has no comorbidities. Laboratory results show normal renal and liver function. What advice should be given about continuing weight loss management?
- A. Orlistat can be prescribed; continue current lifestyle measures and review in 3 months
- B. Increase follow-up intensity and reassess at 6 months before considering orlistat
- C. Refer to specialist weight management services as first-line orlistat has not achieved target
- D. Prescribe orlistat only if she loses an additional 1% body weight in the next month
- E. Continue lifestyle interventions alone and do not prescribe orlistat as target not met (Correct Answer)
Explanation: ***Continue lifestyle interventions alone and do not prescribe orlistat as target not met*** - According to **NICE guidelines**, orlistat should only be prescribed or continued if a patient has lost at least **5% of their initial body weight** through lifestyle changes alone before starting medication. - This patient has achieved a **4% weight loss**, which—while positive—falls short of the required clinical threshold to justify the addition of pharmacological therapy at this review. *Orlistat can be prescribed; continue current lifestyle measures and review in 3 months* - Prescribing orlistat now is premature because the patient has not yet demonstrated the mandatory **5% weight loss** required by clinical criteria for initiation. - **Lifestyle modifications** should remain the primary focus until the specific weight loss targets are met to ensure medication efficacy and patient commitment. *Increase follow-up intensity and reassess at 6 months before considering orlistat* - While increasing support is beneficial, the standard review period for assessing the impact of lifestyle interventions regarding orlistat initiation is typically **3 months**, not 6. - Delaying the reassessment to 6 months may lead to a loss of patient **motivation** and momentum in their current weight loss progress. *Refer to specialist weight management services as first-line orlistat has not achieved target* - **Specialist referral (Tier 3/4 services)** is generally reserved for patients with a **BMI ≥40 kg/m²** or ≥35 kg/m² with significant comorbidities, which this patient does not have. - The patient is currently managed successfully in **primary care**, and there is no evidence that primary care interventions have been exhausted or failed. *Prescribe orlistat only if she loses an additional 1% body weight in the next month* - Guidelines specify a **cumulative 5% weight loss** from baseline, but they do not prescribe a specific "1% per month" additional hurdle for drug initiation. - Artificially setting a one-month deadline is not a standard protocol and does not align with the **long-term behavioral approach** recommended for obesity management.
Question 25: A 55-year-old man with schizophrenia attends for his annual physical health check. He takes olanzapine 20 mg daily. His BMI is 33 kg/m², waist circumference 108 cm, blood pressure 138/86 mmHg, fasting glucose 6.2 mmol/L, HbA1c 43 mmol/mol, total cholesterol 5.4 mmol/L, HDL 0.9 mmol/L, and triglycerides 2.8 mmol/L. Which diagnosis is most likely based on these findings?
- A. Impaired glucose tolerance
- B. Metabolic syndrome (Correct Answer)
- C. Type 2 diabetes mellitus
- D. Familial hypercholesterolaemia
- E. Isolated hypertriglyceridaemia
Explanation: ***Metabolic syndrome*** - The patient meets five criteria for **metabolic syndrome**: increased **waist circumference** (108 cm > 102 cm), elevated **triglycerides** (2.8 mmol/L > 1.7 mmol/L), low **HDL** (0.9 mmol/L < 1.0 mmol/L), elevated **blood pressure** (138/86 mmHg > 130/85 mmHg), and raised **fasting glucose** (6.2 mmol/L > 5.6 mmol/L).- The use of **olanzapine**, a second-generation antipsychotic, is associated with a significantly increased risk of developing **metabolic syndrome** due to its effects on weight gain, glucose, and lipid metabolism.*Impaired glucose tolerance* - This diagnosis typically requires a **2-hour plasma glucose** between 7.8 and 11.0 mmol/L following a **75g oral glucose tolerance test (OGTT)**, which was not performed in this case.- While the patient has **impaired fasting glucose** (6.1–6.9 mmol/L) and **prediabetes** (HbA1c 43 mmol/mol or 6.1%), these are specific components of glucose dysregulation, not the overarching diagnosis that encompasses all his metabolic abnormalities.*Type 2 diabetes mellitus* - Diagnosis of **Type 2 diabetes** requires a **fasting glucose** ≥ 7.0 mmol/L or an **HbA1c** ≥ 48 mmol/mol (6.5%), and this patient's values (6.2 mmol/L and 43 mmol/mol respectively) fall below these thresholds.- Although he has multiple risk factors and features consistent with **insulin resistance**, he is currently classified as having **prediabetes** rather than established diabetes.*Familial hypercholesterolaemia* - This condition is primarily characterized by significantly elevated **LDL cholesterol** (often > 5.0 mmol/L) from birth, leading to early cardiovascular disease, and typically has a strong family history.- This patient's dyslipidaemia primarily involves **high triglycerides** and **low HDL**, with a total cholesterol of 5.4 mmol/L which is not severely elevated, making a genetic **LDL receptor defect** less likely than metabolically induced dyslipidemia.*Isolated hypertriglyceridaemia* - This diagnosis is inappropriate because the patient presents with a cluster of other significant metabolic abnormalities, including **abdominal obesity**, **hypertension**, **low HDL**, and **impaired fasting glucose**.- The elevated **triglycerides** are part of a broader systemic metabolic dysfunction, most accurately captured by the diagnosis of **metabolic syndrome**, rather than an isolated finding.
Question 26: A 72-year-old woman attends for review. She has a 3.5 cm infrarenal abdominal aortic aneurysm (AAA) detected 18 months ago through the NHS screening programme. Her latest ultrasound shows the aneurysm has grown to 4.8 cm (increase of 1.3 cm in 18 months). She is asymptomatic. What is the most appropriate next step in her management?
- A. Continue annual ultrasound surveillance
- B. Increase surveillance to 3-monthly intervals
- C. Arrange urgent vascular surgery referral for consideration of repair (Correct Answer)
- D. Arrange CT angiography and routine vascular surgery referral
- E. Reassure that growth is within expected parameters and continue 6-monthly surveillance
Explanation: ***Arrange urgent vascular surgery referral for consideration of repair*** - This patient's aneurysm has shown **rapid expansion**, growing by **1.3 cm in 18 months**. This rate of growth, even if not strictly >1 cm in 12 months, is considered significant and indicates a higher risk of rupture, requiring an **urgent vascular referral** for evaluation of repair. - The current size of **4.8 cm** combined with this rapid growth necessitates immediate specialist assessment rather than continued surveillance, as it approaches the threshold for intervention. *Continue annual ultrasound surveillance* - **Annual surveillance** is typically recommended for smaller **Abdominal Aortic Aneurysms (AAA)**, generally those measuring between **3.0 cm and 4.4 cm**. - This patient's aneurysm, now **4.8 cm** and demonstrating **rapid growth**, falls outside the parameters for annual monitoring. *Increase surveillance to 3-monthly intervals* - While **3-monthly surveillance** is appropriate for asymptomatic AAAs between **4.5 cm and 5.4 cm**, the presence of **rapid expansion** (1.3 cm in 18 months) elevates the risk beyond what can be managed by increased surveillance alone. - The **rate of growth** is a critical factor and, in this case, necessitates a specialist referral for potential intervention. *Arrange CT angiography and routine vascular surgery referral* - The **rapid expansion** observed makes a **routine vascular surgery referral** inappropriate; the situation demands an **urgent assessment** due to the increased risk of rupture. - While **CT angiography** is essential for pre-operative planning, the initial and most critical step is the **urgent referral** to a vascular surgeon who will then guide further diagnostic steps. *Reassure that growth is within expected parameters and continue 6-monthly surveillance* - A growth of **1.3 cm in 18 months** is considered significant and **not within expected benign parameters** for an AAA, particularly when compared to a threshold of >1 cm in 12 months. - **6-monthly surveillance** is not a standard interval in the NHS AAA screening guidelines, which typically use annual or 3-monthly intervals based on size.
Question 27: A 59-year-old man attends for lifestyle advice. He drinks 4 units of alcohol daily (28 units per week), exclusively in the evenings. He has no alcohol-related health problems and scores 8 on the AUDIT questionnaire. According to NICE guidance on alcohol interventions, what is the most appropriate initial management?
- A. Reassure and advise to continue current drinking pattern
- B. Offer brief intervention focusing on cutting down (Correct Answer)
- C. Refer to specialist alcohol services
- D. Prescribe acamprosate for alcohol reduction
- E. Arrange admission for medically-assisted alcohol withdrawal
Explanation: ***Offer brief intervention focusing on cutting down*** - The patient consumes **28 units per week**, which exceeds the recommended low-risk limit of 14 units, and his **AUDIT score of 8** categorizes him as an **increasing risk drinker** according to NICE guidelines. - For individuals in the increasing risk category, NICE recommends a **brief intervention**, involving structured advice and support to help them reduce their alcohol consumption. *Reassure and advise to continue current drinking pattern* - Reassurance is inappropriate as consuming **28 units per week** significantly exceeds the low-risk guideline, increasing long-term health risks. - An **AUDIT score of 8** indicates a need for active intervention, not simply continuing the current pattern, to mitigate future harm. *Refer to specialist alcohol services* - Referral to specialist alcohol services is generally reserved for individuals with **higher-risk drinking** (AUDIT 16-19) or diagnosed **alcohol dependence** (AUDIT 20+). - This patient's drinking pattern and AUDIT score do not meet the criteria for immediate specialist referral; a primary care intervention is more appropriate. *Prescribe acamprosate for alcohol reduction* - **Acamprosate** is a medication used to help maintain **abstinence** in patients with a history of **alcohol dependence** who have already undergone withdrawal. - It is not indicated for **increasing risk drinkers** who are not dependent and whose primary need is to reduce consumption through behavioral changes. *Arrange admission for medically-assisted alcohol withdrawal* - Medically-assisted alcohol withdrawal is necessary for individuals with significant **physical alcohol dependence** at risk of severe withdrawal symptoms like seizures or delirium tremens. - The patient exhibits no signs of physical dependence or withdrawal symptoms that would necessitate acute medical detoxification or hospital admission.
Question 28: A 36-year-old woman attends with her cervical screening result showing hrHPV positive with normal cytology. She asks about HPV vaccination. She was too old to receive the HPV vaccine in school but wonders if vaccination now would be helpful. What is the most appropriate advice regarding HPV vaccination in this situation?
- A. Vaccination is recommended and will clear her current HPV infection
- B. Vaccination may provide protection against other HPV types but will not clear existing infection (Correct Answer)
- C. Vaccination is contraindicated in women with positive hrHPV results
- D. Vaccination should be delayed until her next cervical screening in 12 months
- E. Vaccination is only effective if given before first sexual contact
Explanation: ***Vaccination may provide protection against other HPV types but will not clear existing infection*** - The HPV vaccine is **prophylactic**, not therapeutic; it helps prevent new infections from the types covered by the vaccine (e.g., **Gardasil 9**) that the patient has not yet encountered. - While it cannot treat or **clear existing hrHPV**, it remains beneficial for adult women to prevent future infection with different **oncogenic strains**. *Vaccination is recommended and will clear her current HPV infection* - Clinical trials have conclusively shown that HPV vaccines have **no therapeutic effect** on pre-existing HPV infections or related **cervical lesions**. - Advising that it will clear her current infection is medically incorrect and may provide a **false sense of security** regarding her follow-up. *Vaccination is contraindicated in women with positive hrHPV results* - A positive **hrHPV test** is not a contraindication; the vaccine is safe to administer to individuals already exposed to or infected with the virus. - There is no evidence of **increased adverse effects** or worsened disease progression when vaccinating HPV-positive individuals. *Vaccination should be delayed until her next cervical screening in 12 months* - There is no clinical requirement to delay vaccination based on **cytology** or **HPV status**, as the vaccine's utility is independent of current infection. - The patient's management plan (repeat testing in 12 months) remains the same regardless of whether she chooses to receive the vaccine now. *Vaccination is only effective if given before first sexual contact* - While **maximum efficacy** is achieved when administered prior to **sexual debut**, the vaccine still offers significant protection to sexually active adults. - It is unlikely an individual has been exposed to all **nine strains** covered by modern vaccines, making it effective for prevention of other types.
Question 29: A 68-year-old man with type 2 diabetes attends following his diabetic eye screening. The report states 'R1M1S0' for the right eye and 'R1M0S0' for the left eye. What action should be taken based on these grading results?
- A. Routine annual screening in 12 months
- B. Accelerated screening in 6 months
- C. Urgent ophthalmology referral within 2 weeks
- D. Routine ophthalmology referral within 13 weeks (Correct Answer)
- E. Immediate same-day ophthalmology referral
Explanation: ***Routine ophthalmology referral within 13 weeks***- The **M1 grading** in the right eye signifies **maculopathy**, indicating diabetic changes affecting the **macula**.- **Maculopathy (M1)** necessitates a **routine ophthalmology referral** for further assessment and potential treatment, typically within **13 weeks**, to prevent vision loss.*Routine annual screening in 12 months*- This interval is appropriate for patients with **R0M0** (no retinopathy) or **R1M0** (background retinopathy without maculopathy).- The presence of **M1 (maculopathy)** requires prompt specialist evaluation, as annual screening would delay necessary intervention for a condition threatening central vision.*Accelerated screening in 6 months*- **Accelerated screening** (e.g., 6 months) is typically recommended for **R2 (pre-proliferative retinopathy)** without maculopathy, where close monitoring is indicated.- **Maculopathy (M1)** warrants a direct **specialist referral** rather than just a shorter screening interval, due to the direct impact on central vision.*Urgent ophthalmology referral within 2 weeks*- An **urgent referral** (within 2 weeks) is usually reserved for **R3 (proliferative diabetic retinopathy)** with high-risk features like new vessels, or severe active maculopathy with rapid vision changes.- While M1 is significant, it generally follows a **routine referral pathway** unless accompanied by acute severe symptoms or proliferative features.*Immediate same-day ophthalmology referral*- **Same-day referral** is reserved for true ophthalmic emergencies, such as **retinal detachment**, acute angle-closure glaucoma, or sudden severe vision loss potentially from vitreous hemorrhage due to R3.- **R1M1** describes established diabetic retinopathy and maculopathy, which, while serious, does not typically constitute a same-day emergency unless acute, rapid changes are noted.
Question 30: A 42-year-old woman with a BMI of 34 kg/m² attends for weight management advice. She has tried multiple diets without sustained success. She asks about orlistat. Her blood pressure is 142/88 mmHg and HbA1c is 41 mmol/mol. According to NICE guidance, what is the minimum BMI threshold at which orlistat can be prescribed for this patient?
- A. BMI ≥25 kg/m²
- B. BMI ≥28 kg/m² (Correct Answer)
- C. BMI ≥30 kg/m²
- D. BMI ≥32 kg/m²
- E. BMI ≥35 kg/m²
Explanation: ***BMI ≥28 kg/m²*** - According to **NICE guidelines**, orlistat may be prescribed for patients with a **BMI ≥28 kg/m²** if they have associated **co-morbidities**, such as hypertension or type 2 diabetes. - This patient qualifies at this lower threshold because she has **hypertension** (142/88 mmHg), making orlistat a valid pharmacological option. *BMI ≥25 kg/m²* - A **BMI ≥25 kg/m²** is the threshold for being classified as **overweight**, but it does not meet the pharmacological intervention criteria for orlistat. - **Weight management** at this level typically focuses exclusively on diet, exercise, and lifestyle modifications rather than medication. *BMI ≥30 kg/m²* - This is the standard threshold for prescribing orlistat in patients who have **no co-morbidities**. - While this patient’s BMI of 34 exceeds this, the **minimum threshold** is lower (28) because of her existing clinical risk factor (hypertension). *BMI ≥32 kg/m²* - This is not a standard NICE diagnostic threshold for initiating orlistat therapy in the general population. - However, lower thresholds (starting at **BMI 27.5 kg/m²**) may be considered for individuals from **South Asian** or other minority ethnic groups due to increased metabolic risk. *BMI ≥35 kg/m²* - This threshold is often used in the context of referring patients for **Tier 3 specialist weight management** services or considering **bariatric surgery** if co-morbidities exist. - Orlistat is available much earlier in the treatment pathway to prevent progression to this level of obesity.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free